# AMVUTTRA® (vutrisiran) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vutrisiran

> The FDA approved AMVUTTRA® (vutrisiran), sponsored by ALNYLAM PHARMACEUTICALS, INC. (ALNY), on March 20, 2025 for ATTR Amyloidosis with Cardiomyopathy.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AMVUTTRA® (vutrisiran) |
| Codes |  |
| Sponsor | ALNYLAM PHARMACEUTICALS, INC. (ALNY) https://sec-api.dev/companies/alny/catalysts |
| Indications | cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, [attr amyloidosis with cardiomyopathy](https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy), with attr amyloidosis with cardiomyopathy, [Transthyretin Amyloidosis (ATTR) With Cardiomyopathy](https://sec-api.dev/indications/transthyretin-amyloidosis-attr-with-cardiomyopathy) |
| Modality | sirna |
| FDA designations | orphan |

## Timeline

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month. Indication: ATTR amyloidosis with cardiomyopathy.
- First seen 2025-02-13, last confirmed 2025-02-13.
- SEC Form 10-K (accession 0001178670-25-000026): "In June 2024, we reported positive topline results from the HELIOS-B clinical trial of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In June 2024, we announced positive topline results, noting that study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events during the double-blind period in both the overall population and in the monotherapy population." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### October 9, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-02-13, last confirmed 2025-02-13.
- SEC Form 10-K (accession 0001178670-25-000026): "On October 9, 2024, we announced that we had filed a supplemental New Drug Application, or sNDA, with the United States Food and Drug Administration, or the FDA, using a Priority Review Voucher." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In August and September 2024, we reported detailed results from the HELIOS-B clinical trial, and on October 9, 2024, we announced that we had filed an sNDA with the FDA, using a Priority Review Voucher." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### Nov 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-13, last confirmed 2025-02-13.
- SEC Form 10-K (accession 0001178670-25-000026): "In November 2024, the FDA accepted our sNDA submission for review for vutrisiran, with an action date set for March 23, 2025 under the Prescription Drug User Fee Act, or PDUFA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In November 2024, the FDA accepted our sNDA submission for review for vutrisiran, with an action date set for March 23, 2025 under PDUFA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### March 20, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: ATTR Amyloidosis with Cardiomyopathy.
- First seen 2025-03-21, last confirmed 2025-03-21.
- Press release filed with the SEC (EX-99) (accession 0001178670-25-000038): "Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)" https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm

### March 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis.
- First seen 2025-03-21, last confirmed 2026-02-12.
- Press release filed with the SEC (EX-99) (accession 0001178670-25-000038): "CAMBRIDGE, Mass. -- Mar. 20, 2025—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm
- SEC Form 8-K (accession 0001178670-25-000038): "On March 20, 2025, Alnylam Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the United States Food and Drug Administration approved its supplemental new drug application for AMVUTTRA® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/alny-20250320.htm
- SEC Form 10-K (accession 0001628280-26-007497): "In March 2025, the FDA approved our sNDA for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm

### March 23, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: with ATTR amyloidosis with cardiomyopathy.
- First seen 2025-01-13, last confirmed 2025-02-13.
- Press release filed with the SEC (EX-99) (accession 0001178670-25-000008): "** Guidance assumes FDA approval of the sNDA for vutrisiran for the treatment of adults with ATTR amyloidosis with cardiomyopathy by the March 23, 2025 PDUFA target action date." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In November 2024, the FDA accepted our sNDA submission for review for vutrisiran, with an action date set for March 23, 2025 under the Prescription Drug User Fee Act, or PDUFA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In November 2024, the FDA accepted our sNDA submission for review for vutrisiran, with an action date set for March 23, 2025 under PDUFA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001178670-25-000008): "•Achieve U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application for the treatment of adults with ATTR amyloidosis with cardiomyopathy by the PDUFA target action date of March 23, 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001178670-25-000038): "Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)" https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06679946 (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT06679946

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06679946 (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT06679946

## Same indication

- [NTLA-2001](https://sec-api.dev/pdufa/ntla-2001) (NTLA)
- [Nucresiran](https://sec-api.dev/pdufa/nucresiran) (ALNY)
- [ONPATTRO® (patisiran)](https://sec-api.dev/pdufa/patisiran) (ALNY)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vutrisiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMVUTTRA® (vutrisiran) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vutrisiran

```bibtex
@misc{secapidev_pdufa_vutrisiran_20261116,
  title        = {AMVUTTRA® (vutrisiran) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vutrisiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vutrisiran_20261116","title":"AMVUTTRA® (vutrisiran) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vutrisiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
